dc.contributor.author | Constantinidou, Anastasia | en |
dc.contributor.author | Martin, Axel | en |
dc.contributor.author | Sharma, Bhupinder | en |
dc.contributor.author | Johnston, Stephen R. D. | en |
dc.creator | Constantinidou, Anastasia | en |
dc.creator | Martin, Axel | en |
dc.creator | Sharma, Bhupinder | en |
dc.creator | Johnston, Stephen R. D. | en |
dc.date.accessioned | 2018-06-22T09:52:50Z | |
dc.date.available | 2018-06-22T09:52:50Z | |
dc.date.issued | 2011 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41536 | |
dc.description.abstract | Background: Despite the increasing use of positron emission tomography/computed tomography (PET/CT) in the management of patients with breast cancer, its role is yet to be defined. Patients and methods: We reviewed PET/CT scans carried out in breast cancer patients, the indication, concordance/discordance with other imaging and whether their use had altered patient management. Results: PET/CT scans (233) were carried out in 122 patients between July 2004 and October 2008. Indications were as follows: staging (S) (91), response assessment (RA) (87), clarification (C) of findings on other imaging (32) and reassurance (ASS) (23). In the S group, positive scans were helpful in accurately defining the extent of disease and guided localised or systemic treatment. PET/CT was particularly useful for detecting lytic bone metastases. One-third of the scans was carried out for RA. PET/CT allowed early RA and in some cases appropriate discontinuation of ineffective treatment. PET/CT was used effectively for the clarification of indeterminate lesions on CT (18), magnetic resonance imaging (15) and bone scan (13). In the ASS group, all scans were negative. Conclusions: PET/CT is useful in accurately staging metastatic disease, assessing response to systemic treatment and clarifying equivocation on other imaging. Incorporation of PET/CT in these areas contributes to breast cancer management optimisation. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Metastatic breast cancer | en |
dc.subject | Pet/ct | en |
dc.subject | Response assessment | en |
dc.subject | Staging | en |
dc.title | Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: A large retrospective study from the Royal Marsden Hospital | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdq343 | |
dc.description.volume | 22 | |
dc.description.issue | 2 | |
dc.description.startingpage | 307 | |
dc.description.endingpage | 314 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Constantinidou, Anastasia [0000-0001-5316-7574] | |
dc.contributor.orcid | Sharma, Bhupinder [0000-0002-5922-9630] | |
dc.contributor.orcid | Martin, Axel [0000-0002-4665-9113] | |
dc.gnosis.orcid | 0000-0001-5316-7574 | |
dc.gnosis.orcid | 0000-0002-5922-9630 | |
dc.gnosis.orcid | 0000-0002-4665-9113 | |